Why the study?
Does PEG-rHuMGDF increase functional platelet production in subjects with advanced solid tumors?
Population
Subjects with advanced solid tumors
Design
Cohort
Follow-up
up to day 16
Authors
Loading...
Supports functional platelet increases in advanced solid tumors; hypothesis-generating for thrombocytopenia, requiring randomized confirmation before practice change.
Does PEG-rHuMGDF increase functional platelet production in subjects with advanced solid tumors?
Administration of PEG-rHuMGDF to humans with advanced solid tumors effectively increases the circulating count of fully functional, non-activated platelets.
O’Malley et al. (1996) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: